Search
                    Healthy Participants Clinical Trials
A listing of 28  Healthy Participants  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 28
        
                There are currently 28 active clinical trials seeking participants for Healthy Participants research studies. The states with the highest number of trials for Healthy Participants participants are California, Florida, Texas and Maryland.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Adult Vaccine Clinical Trial
            
        Recruiting
            
        Looking to boost your immunity?
You may be interested in participating in an Adult Vaccine Clinical Trial.
The Adult Vaccine Research Studies are looking for adults to evaluate the effectiveness of a potential vaccine.
    You may be interested in participating in an Adult Vaccine Clinical Trial.
The Adult Vaccine Research Studies are looking for adults to evaluate the effectiveness of a potential vaccine.
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    
                
                                    A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants
                                
            
            
        Recruiting
                            
            
                The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 55 years
            Trial Updated:
                08/21/2025
            
            Locations: Fortrea Clinical Research Unit Inc., Madison, Wisconsin         
        
        
            Conditions: Healthy Participants
        
            
        
    
                
                                    Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
                                
            
            
        Recruiting
                            
            
                This study will be conducted to assess the safety, tolerability, and pharmacokinetics of INCB000631 when administered orally to healthy adult participants.             
        
        
    Gender:
                ALL
            Ages:
                Between 19 years and 55 years
            Trial Updated:
                08/15/2025
            
            Locations: Celerion, Inc, Lincoln, Nebraska         
        
        
            Conditions: Healthy Participants
        
            
        
    
                
                                    FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
                                
            
            
        Recruiting
                            
            
                The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                08/14/2025
            
            Locations: Anaheim Clinical Trials, LLC, Anaheim, California         
        
        
            Conditions: Healthy Participants, Atopic Dermatitis
        
            
        
    
                
                                    Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.             
        
        
    Gender:
                MALE
            Ages:
                Between 18 years and 55 years
            Trial Updated:
                08/12/2025
            
            Locations: ICON Clinical Research: Lenexa, Lenexa, Kansas  +1 locations         
        
        
            Conditions: Healthy Participants
        
            
        
    
                
                                    A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to assess the impact of multiple doses of itraconazole on the pharmacokinetics (PK) of AZD5004 in healthy participants (Part A), and to assess the impact of multiple doses of AZD5004 on the PK of Combined Oral Contraceptives (COCs) in healthy female participants (Part B).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                08/08/2025
            
            Locations: Research Site, Baltimore, Maryland  +1 locations         
        
        
            Conditions: Healthy Participants
        
            
        
    
                
                                    A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 55 years
            Trial Updated:
                08/07/2025
            
            Locations: Research Site, Glendale, California         
        
        
            Conditions: Healthy Participants
        
            
        
    
                
                                    Effect of Caloric Content and Timing of Meal on Postprandial Substrate Oxidation and Pulse Wave Analysis
                                
            
            
        Recruiting
                            
            
                The overarching aim of this research is to study the effects of caloric content and timing of meals on measures of postprandial metabolism and cardiovascular response
1. Determine the effect of caloric content on measures of postprandial metabolic flexibility and pulse wave analysis to a mixed meal challenge.
2. Determine the effect of meal timing on measures of postprandial metabolic flexibility and pulse wave analysis to a mixed meal challenge.
Hypothesis: We hypothesize: 1) that hypercalori...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 45 years
            Trial Updated:
                08/07/2025
            
            Locations: George Washington University School of Public Health, Washington, District of Columbia         
        
        
            Conditions: Feeding, Metabolism, Indirect Calorimetry, Blood Flow Velocity, Pulse Wave Analysis, Pulse Wave Velocity, Carbohydrate Metabolism, Fatty Acid Metabolism, Healthy Participants
        
            
        
    
                
                                    A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels
                                
            
            
        Recruiting
                            
            
                The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\[a\]) levels.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 55 years
            Trial Updated:
                08/06/2025
            
            Locations: Research Site, Glendale, California  +3 locations         
        
        
            Conditions: Healthy Participants
        
            
        
    
                
                                    A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
                                
            
            
        Recruiting
                            
            
                The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.             
        
        
    Gender:
                MALE
            Ages:
                Between 18 years and 85 years
            Trial Updated:
                08/01/2025
            
            Locations: Orlando Clinical Research Center ( Site 0002), Orlando, Florida  +1 locations         
        
        
            Conditions: Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants
        
            
        
    
                
                                    A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
                                
            
            
        Recruiting
                            
            
                Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer.
The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.             
        
        
    Gender:
                MALE
            Ages:
                18 years and above
            Trial Updated:
                08/01/2025
            
            Locations: Clinical Pharmacology of Miami ( Site 0002), Miami, Florida  +1 locations         
        
        
            Conditions: Hepatic Impairment, Healthy Participants
        
            
        
    
                
                                    A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
                                
            
            
        Recruiting
                            
            
                This study will measure the effects of multiple doses of AZD6234 and a combination of AZD6234 and AZD9550 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 35 years and 75 years
            Trial Updated:
                07/31/2025
            
            Locations: Research Site, Glendale, California  +1 locations         
        
        
            Conditions: Healthy Participants
        
            
        
    
                
                                    A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
                                
            
            
        Recruiting
                            
            
                This study is conducted to assess the effect of itraconazole, rifampin, and acid-reducing agents on INCB161734 pharmacokinetics when administered orally in healthy participants.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 55 years
            Trial Updated:
                07/31/2025
            
            Locations: Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison, Madison, Wisconsin         
        
        
            Conditions: Healthy Participants
        
            
        
    1 - 12 of 28
            